Gilead Sciences, Inc., valued at $147.4 billion, is a U.S. biopharmaceutical company focusing on HIV/AIDS, hepatitis, COVID-19, and other diseases. Its stock has outperformed the S&P 500, up 28.2% YTD. Gilead’s Q3 2025 earnings showed $7.8 billion in revenue and strong profit growth. Analysts expect EPS to grow 74.7% this fiscal year.

Gilead’s success is attributed to its HIV drugs, new therapies, attractive valuation, and improved earnings guidance. Analysts have a “Moderate Buy” consensus on GILD stock, with a mean price target of $128.42, representing an 8.4% premium. Wells Fargo analyst maintains a “Buy” rating and $140 price target.

In Q3 2025, Gilead posted $7.8 billion in revenue, a 3% increase YoY. Product sales were $7.3 billion, down 2% YoY, but excluding COVID-19 antiviral, sales rose 4% to $7.1 billion. The company projects FY2025 product sales between $28.4 billion and $28.7 billion, with non-GAAP EPS between $8.05 and $8.25. Analysts expect GILD’s EPS to grow 74.7% this fiscal year.

Read more at Yahoo Finance: Is Wall Street Bullish or Bearish on Gilead Sciences Stock?